Notification of changes to medicinal cannabis and nicotine product submission and listing processes
To ensure consistency in the management of all medicinal products, we are enforcing our standard product submission process effective from 31 January 2025. This process aligns with how all other medicinal products are managed within Best Practice Software and is essential for maintaining standardised, consistent product handling to eliminate inconsistencies and improve patient safety.
Changes to the Product Submission Process
- Discontinuation of direct bespoke medicinal product submissions.
- From 31 January 2025, Best Practice Software will no longer accept bespoke product submissions via email or other direct channels. This includes medicinal cannabis and nicotine.
- This change ensures data integrity and aligns the handling of medicinal cannabis and nicotine products with our standardised processes for all other drugs.
- Mandatory requirement to have completed MIMS Australia product submission process.
- All product submissions must be completed through MIMS Australia, which provides a centralised platform for capturing and managing product data efficiently.
- AMT Coding via the Australian Digital Health Agency (ADHA).
- To support electronic prescribing and accurate product dispensing, all medicinal products must have an AMT (Australian Medicines Terminology) code.
- AMT coding supports the accurate and consistent monitoring of all S8 and controlled substances, ensuring all prescribed medicinal products outlined in each jurisdiction as monitored, can be tracked.
- Suppliers are required to contact ADHA to obtain AMT coding and ensure their products are added to the AMT.
Important Compliance Information
Best Practice Software receives consistent, compliant drug data monthly from the ADHA (AMT), Services Australia (PBS) and MIMS. This data is curated, verified and tested to ensure clinical safety and minimise risk to patients.
Failure to comply with this new process will result in your products being inaccessible for prescribing within Best Practice Software until the correct submission process is completed. Products submitted outside the designated channels will not be included until they meet the new requirements.
Next Steps
We are confident these changes will streamline product management, reduce redundancy, and enhance data accuracy, ultimately improving patient safety.
Your prompt alignment with the new process is critical to maintaining the inclusion of your products in Best Practice Software. Should you have any questions or require further assistance, please don’t hesitate to contact us.
MIMS Australia process:
Contact MIMS editorial by email (editorial@mims.com.au) outlining your request to list your products. They will advise of their process and their required paperwork.
ADHA process:
Your products can be submitted singularly or batched via their request page – https://www.healthterminologies.gov.au/content-requests/amt-request/ .
Thank you for your cooperation and support.
Kind regards,
Best Practice Software